• About
  • Licensing
  • Podcasting
  • Contact

AudioMedica.com

  • Public Health
  • Oncology
  • Cardiovascular
  • General Medicine

London School of Hygiene & Tropical Medicine Audio News Review, September 12th, 2007

  • — 12 Sep, 2007
AudioMedica News
AudioMedica News
London School of Hygiene & Tropical Medicine Audio News Review, September 12th, 2007
London School of Hygiene & Tropical Medicine Audio News Review, September 12th, 2007
00:00 /
RSS Feed
Share
Link
Embed
Jaime Miranda
Jaime Miranda

Road-Side Tranexamic Acid Therapy to Reduce Mortality and Blood Transfusions after Trauma?

JAIME MIRANDA, London School of Hygiene and Tropical Medicine, Peru
The multi-national CRASH trial investigates whether the antifibrinolytic agent, tranexamic acid normally used to reduce bleeding during surgery can also be used as a first-aid to cut mortality and the need of blood transfusion immediately after trauma. Jaime Miranda, based in Lima, Peru, described to Peter Goodwin how the trial could benefit the developing world in particular.

Steven Grinspoon
Steven Grinspoon
Judith Currier
Judith Currier

Growth Hormones: Slimming Aid for Patients Receiving HAART?

REFERENCE: The Lancet 2007; 370:251-261
STEVEN GRINSPOON, Massachusetts General Hospital, Boston
COMMENT: JUDITH CURRIER, University of California, Los Angeles

Daily administration of the growth hormone releasing factor, TH9507, to patients with HIV receiving Highly Active Anti Retroviral Therapy (HAART) can help to reduce cardiovascular risk factors, according to Steven Grinspoon, who presented a paper on this at the Conference on Retroviruses and Opportunistic Infections, held in Los Angeles. He talked about his study with Dan Keller, who discussed the paper with Judith Currier.

Roy Steigbigel
Roy Steigbigel
John Mellors
John Mellors

Raltegravir Doubled Antiviral Response Rates in Treatment-Experienced HIV-Infected Patients

REFERENCE: The Lancet 2007; 370:251-261
ROY STEIGBIGEL, State University of New York at Stony Brook
COMMENT: JOHN W. MELLORS, University of Pittsburgh

The integrase inhibitor raltegravir (one of a new class of anti-retroviral agents) blocks enzymes that allow HIV’s nuclei acid to integrate into the DNA of host cells. The BENCHMRK study found that patients with HIV who are resistant to at least one drug in each of the nucleoside, non-nucleoside, and protease inhibitor classes, have doubled antiviral response rates and increased CD4 cells when taking raltegravir. Roy Steigbigel explained the study to Dan Keller in Los Angeles. John Mellors commented on the findings.

Anthony Fauci
Anthony Fauci

Non-Perfect HIV Vaccine: Major Benefits

ANTHONY FAUCI, National Institutes of Health, Bethesda
There is good hope that a useful vaccine for HIV will be developed soon. Anthony Fauci wrote in the New England Journal Medicine (and explained to Derek Thorne for Audio News) that although a perfect vaccine may not emerge, a non-perfect vaccine will nevertheless be of great use, by slowing disease progression and also reducing the spread of disease.

[audio:https://www.audiomedica.com/podcasting/lshtm/070830lshtmReview4.mp3]
London School of Hygiene & Tropical Medicine Audio News Review, September 12th, 2007Add to iTunes

You may also like...

  • Miscarriage Risk in Women with Low Body Mass Index Miscarriage Risk in Women with Low Body Mass Index 26 Jan, 2007
  • Rebecca Psutka Boiling Water: No Guarantee For Safe Drinking 30 Mar, 2012
  • Anna Goodman British Indian Children Have Better Mental Health 14 Aug, 2010
  • David Schellenberg Bed-Nets To Prevent Malaria: Latest Research Evidence 20 Sep, 2011
  • Previous story Drug Eluting Stents: Higher Late Mortality in STEMI Patients Than Bare Metal: GRACE Registry Findings
  • Next story LSHTM Audio News Special: Energy and Health
  • News

    • Mandeep Mehra MDCOVID-19 Co-Morbidity Risks Quantified from Three Continents SurveyMay 28, 2020
    • Ultrahypofractionated Radiation Just As Effective for Prostate CancerUltrahypofractionated Radiation Just As Effective for Prostate CancerMay 16, 2018
    • Paracetamol Poisoning: 12-hour modified acetylcysteine treatment for paracetamol poisoning reduced side effects associated with standard regimen.First evidence that genome editing made patients with AIDS more resistant to HIVMarch 8, 2014
    • Paracetamol Poisoning: 12-hour modified acetylcysteine treatment for paracetamol poisoning reduced side effects associated with standard regimen.Anticoagulation with warfarin can be beneficial in patients with atrial fibrillation and chronic kidney disease.March 7, 2014
    • Paracetamol Poisoning: 12-hour modified acetylcysteine treatment for paracetamol poisoning reduced side effects associated with standard regimen.Prostate cancer: Adult exposure to bisphenol-A linked to prostate cancer riskMarch 6, 2014
  • Related interviews

    • CT Screening Cuts Lung Cancer Deaths 24 Per Cent—Second…
    • Volume CT Lung Cancer Screening Cuts Cancer Deaths 24 Per…
    • Genomic-led AML Clinical Decision Making Within Seven Days
    • Microbiome Diversity Key To Survival After Allogeneic…
    • New Front Line Standard for Older Patients with Chronic…
  • Home
  • Public Health
  • London School of Hygiene & Tropical Medicine
  • London School of Hygiene & Tropical Medicine Audio News Review, September 12th, 2007

© Copyright 2022 AudioMedica.com. Typegrid Theme by WPBandit.